Valuation: United Therapeutics Corporation

Market Cap 22.74B 19.94B 18.53B 17.01B 32.04B 2,196B 32.55B 220B 86.19B 1,073B 85.36B 83.54B 3,710B P/E 2026 *
19.9x
P/E 2027 * 17x
Enterprise Value 20.1B 17.62B 16.37B 15.03B 28.32B 1,941B 28.77B 195B 76.17B 948B 75.43B 73.82B 3,278B EV / Sales 2026 *
6.21x
EV / Sales 2027 * 5.13x
Free-Float
53.7%
Yield 2026 *
-
Yield 2027 * -
1 day-1.63%
1 week+0.08%
Current month-2.72%
1 month-1.77%
3 months-8.09%
6 months+12.20%
Current year+8.17%
1 week 521.73
Extreme 521.73
543.56
1 month 520.05
Extreme 520.05
563.7
Current year 455.63
Extreme 455.63
609.35
1 year 272.12
Extreme 272.12
609.35
3 years 208.62
Extreme 208.6249
609.35
5 years 158.38
Extreme 158.38
609.35
10 years 74.31
Extreme 74.31
609.35
Manager TitleAgeSince
Chief Executive Officer 71 1996-06-25
President 54 2016-06-25
Director of Finance/CFO 58 2015-03-12
Director TitleAgeSince
Director/Board Member 78 2001-12-31
Chairman 71 1996-06-25
Director/Board Member 92 2001-12-31
Date Insider Type Main position Quantity % Market Cap.
7/17/26 Fiscal year

Chief Executive Officer

28,500 0.0671%
7/16/26 Fiscal year

Chief Executive Officer

28,500 0.0671%
7/16/26 Fiscal year

General Counsel

24,900 0.0587%
Change 5-day change 1-year change 3-year change Capi.($)
-1.63%+0.08%+79.81%+112.32% 22.74B
-1.05%+0.91%+52.59%+151.71% 1,048B
+2.00%+0.70%+55.53%+50.20% 603B
-1.09%+3.48%+37.03%+76.22% 452B
-0.42%+1.65%+30.05%+21.05% 327B
-0.16%+2.39%+36.91%+37.33% 283B
+1.68%+2.73%+24.14%+17.94% 259B
-1.40%-0.06%-22.24%-42.39% 219B
-0.05%+3.04%+23.72%+55.89% 198B
+0.05%+0.23%+20.37%+61.63% 162B
Average -0.18%+1.74%+33.79%+54.19% 357.44B
Weighted average by Cap. -0.19%+1.69%+38.29%+72.79%

Financials

2026 *2027 *
Net sales 3.24B 2.84B 2.64B 2.42B 4.56B 312B 4.63B 31.34B 12.26B 153B 12.14B 11.88B 528B 3.68B 3.23B 3B 2.75B 5.18B 355B 5.27B 35.64B 13.94B 174B 13.81B 13.51B 600B
Net income 1.25B 1.09B 1.01B 932M 1.75B 120B 1.78B 12.07B 4.72B 58.77B 4.67B 4.57B 203B 1.47B 1.29B 1.2B 1.1B 2.08B 142B 2.11B 14.27B 5.58B 69.53B 5.53B 5.41B 240B
Net Debt -2.65B -2.32B -2.16B -1.98B -3.73B -255B -3.79B -25.63B -10.03B -125B -9.93B -9.72B -432B -3.86B -3.39B -3.15B -2.89B -5.44B -373B -5.53B -37.43B -14.64B -182B -14.5B -14.19B -630B
Logo United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions. It markets and sells commercial products, including Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI), Tyvaso (treprostinil) Inhalation Solution (Nebulized Tyvaso), Remodulin (treprostinil) Injection (Remodulin), Orenitram (treprostinil) Extended-Release Tablets (Orenitram), Unituxin (dinutuximab) Injection (Unituxin) and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and Nebulized Tyvaso to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). Unituxin, an infused monoclonal antibody for the treatment of high-risk neuroblastoma and for the treatment of neuroblastoma after high-dose chemotherapy. Adcirca, an oral immediate-release tablet form of the PDE-5 inhibitor tadalafil. Its THY-100 is in preclinical development for congenital athymia.
Employees
1,400
Date Price Change Volume
26-07-22 US$527.07 -1.63% 461,431
26-07-21 US$535.83 +1.23% 467,386
26-07-20 US$529.34 -1.18% 318,879
26-07-17 US$535.67 +1.25% 422,243
26-07-16 US$529.05 -0.52% 350,858
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
527.07USD
Average target price
663.08USD
Spread / Average Target
+25.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. UTHR Stock